{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:07:29Z","timestamp":1790665649401,"version":"4.1.0"},"reference-count":220,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01723","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T10:57:04Z","timestamp":1601463424000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals"],"prefix":"10.3389","volume":"10","author":[{"given":"Polina","family":"Shindiapina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elshafa H.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mozhenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamrat","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr virus infection.","volume":"102","author":"Dunmire","year":"2018","journal-title":"J Clin Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.","volume":"55","author":"Al Hamed","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"B3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/hon.155_2631","article-title":"Clinical outcomes in patients with Epstein-Barr virus (EBV)-positive non-B cell lymphoma at the Ohio state university James comprehensive cancer center (OSU JAMES CCC).","volume":"37","author":"Brammer","year":"2019","journal-title":"Hematol Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","article-title":"Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.","volume":"113","author":"Chetaille","year":"2009","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1158\/1078-0432.Ccr-06-2823","article-title":"Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.","volume":"13","author":"Oyama","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/1469-0691.12534","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.","volume":"20","author":"San-Juan","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/cncr.25547","article-title":"Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States.","volume":"117","author":"Simard","year":"2011","journal-title":"Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/jco.2008.19.6626","article-title":"Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.","volume":"27","author":"Powles","year":"2009","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein-Barr virus-associated lymphomas.","volume":"372","author":"Shannon-Lowe","year":"2017","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1084\/jem.138.6.1365","article-title":"Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes.","volume":"138","author":"Jondal","year":"1973","journal-title":"J. Exp Med."},{"key":"B11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1128\/JVI.55.2.347-351.1985","article-title":"Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).","volume":"55","author":"Nemerow","year":"1985","journal-title":"J Virol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.10591.1","article-title":"Recent advances in understanding Epstein-Barr virus.","volume":"6","author":"Stanfield","year":"2017","journal-title":"F1000Res."},{"key":"B13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/j.1460-2075.1989.tb03356.x","article-title":"Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos.","volume":"8","author":"Farrell","year":"1989","journal-title":"EMBO J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1073\/pnas.0911948107","article-title":"AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome.","volume":"107","author":"Kalla","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B15","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/JVI.57.3.1016-1022.1986","article-title":"trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment.","volume":"57","author":"Takada","year":"1986","journal-title":"J Virol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1128\/jvi.01416-06","article-title":"Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.","volume":"81","author":"Wen","year":"2007","journal-title":"J Virol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1093\/emboj\/19.12.3080","article-title":"The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.","volume":"19","author":"Feederle","year":"2000","journal-title":"EMBO J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/0042-6822(91)90849-7","article-title":"Cooperation of EBV DNA polymerase and EA-D(BMRFl)in vitro and colocalization in nuclei of infected cells.","volume":"184","author":"Kiehl","year":"1991","journal-title":"Virology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"35896","DOI":"10.1074\/jbc.M109.051581","article-title":"Crystal structure of Epstein-Barr virus DNA polymerase processivity factor BMRF1.","volume":"284","author":"Murayama","year":"2009","journal-title":"J Biol Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1006\/viro.1997.8470","article-title":"The Epstein\u2013Barr virus (EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream component of the EBV oriLyt.","volume":"230","author":"Zhang","year":"1997","journal-title":"Virology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1128\/jvi.76.5.2469-2479.2002","article-title":"Epstein-Barr virus BALF1 is a BCL-2-like antagonist of the herpesvirus antiapoptotic BCL-2 proteins.","volume":"76","author":"Bellows","year":"2002","journal-title":"J Virol."},{"key":"B22","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1128\/JVI.73.6.5181-5185.1999","article-title":"Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak.","volume":"73","author":"Marshall","year":"1999","journal-title":"J Virol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1073\/pnas.0901036106","article-title":"The Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim.","volume":"106","author":"Desbien","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001236","article-title":"Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1.","volume":"6","author":"Kvansakul","year":"2010","journal-title":"PLoS Pathog."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1128\/JVI.00063-14","article-title":"Epstein-Barr virus BALF3 has nuclease activity and mediates mature virion production during the lytic cycle.","volume":"88","author":"Chiu","year":"2014","journal-title":"J Virol."},{"key":"B26","first-page":"1711","article-title":"The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes.","volume":"11","author":"Stuart","year":"1995","journal-title":"Oncogene."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1128\/jvi.00170-09","article-title":"The Epstein-Barr virus alkaline exonuclease BGLF5 serves pleiotropic functions in virus replication.","volume":"83","author":"Feederle","year":"2009","journal-title":"J Virol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1128\/JVI.01613-08","article-title":"Primary B-cell infection with a deltaBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T-cell response.","volume":"83","author":"Neuhierl","year":"2009","journal-title":"J Virol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"15036","DOI":"10.1073\/pnas.232381299","article-title":"Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection.","volume":"99","author":"Neuhierl","year":"2002","journal-title":"Proc Natl Acad Sci USA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0092-8674(87)90216-9","article-title":"Epstein-Barr virus gp350\/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis.","volume":"50","author":"Tanner","year":"1987","journal-title":"Cell."},{"key":"B31","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/JVI.64.8.3753-3759.1990","article-title":"The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner.","volume":"64","author":"Holley-Guthrie","year":"1990","journal-title":"J Virol."},{"key":"B32","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1128\/JVI.63.4.1729-1736.1989","article-title":"The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters.","volume":"63","author":"Kenney","year":"1989","journal-title":"J Virol."},{"key":"B33","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/nar\/21.8.1999","article-title":"Direct BRLF1 binding is required for cooperative BZLF1\/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1.","volume":"21","author":"Quinlivan","year":"1993","journal-title":"Nucleic Acids Res."},{"key":"B34","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1128\/JVI.61.12.3672-3679.1987","article-title":"Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency.","volume":"61","author":"Countryman","year":"1987","journal-title":"J Virol."},{"key":"B35","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1128\/JVI.66.8.5030-5039.1992","article-title":"trans-acting requirements for replication of Epstein-Barr virus ori-Lyt.","volume":"66","author":"Fixman","year":"1992","journal-title":"J Virol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007214","article-title":"Early events associated with infection of Epstein-Barr virus infection of primary B-cells.","volume":"4","author":"Halder","year":"2009","journal-title":"PLoS One."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1128\/JVI.78.10.5194-5204.2004","article-title":"Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells.","volume":"78","author":"Hochberg","year":"2004","journal-title":"J Virol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1074-7613(02)00318-7","article-title":"The dispersal of mucosal memory B cells: evidence from persistent EBV infection.","volume":"16","author":"Laichalk","year":"2002","journal-title":"Immunity."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1099\/0022-1317-71-7-1481","article-title":"Different Epstein\u2014Barr virus\u2014B cell interactions in phenotypically distinct clones of a Burkittandapos;s lymphoma cell line.","volume":"71","author":"Gregory","year":"1990","journal-title":"J Gen Virol."},{"key":"B40","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1002\/j.1460-2075.1987.tb02568.x","article-title":"Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt\u2019s lymphoma cells.","volume":"6","author":"Rowe","year":"1987","journal-title":"EMBO J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/pbc.24319","article-title":"Demonstration of type II latency in T lymphocytes of Epstein\u2013Barr virus-associated hemophagocytic lymphohistiocytosis.","volume":"60","author":"Ito","year":"2013","journal-title":"Pediatr Blood Cancer."},{"key":"B42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1182\/blood-2010-01-265272","article-title":"STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus\u2013encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma.","volume":"117","author":"Kis","year":"2011","journal-title":"Blood."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1099\/0022-1317-69-5-1051","article-title":"Epstein\u2014Barr virus gene expression in nasopharyngeal carcinoma.","volume":"69","author":"Young","year":"1988","journal-title":"J Gen Virol."},{"key":"B44","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1128\/JVI.67.6.3182-3190.1993","article-title":"Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency.","volume":"67","author":"Brooks","year":"1993","journal-title":"J Virol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jim.2012.08.008","article-title":"Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.","volume":"385","author":"Rasul","year":"2012","journal-title":"J Immunol Methods."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01926-15","article-title":"Consideration of Epstein-Barr virus-encoded noncoding RNAs EBER1 and EBER2 as a functional backup of viral oncoprotein latent membrane protein 1.","volume":"7","author":"Herbert","year":"2016","journal-title":"mBio."},{"key":"B47","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1053\/j.seminoncol.2014.12.030","article-title":"Epstein-Barr virus\u2013associated lymphomas.","volume":"42","author":"Grywalska","year":"2015","journal-title":"Semin Oncol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10070213","article-title":"Human oncoviruses and p53 tumor suppressor pathway deregulation at the origin of human cancers.","volume":"10","author":"Tornesello","year":"2018","journal-title":"Cancers."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/blood.2019001880","article-title":"The whole-genome landscape of Burkitt lymphoma subtypes.","volume":"134","author":"Panea","year":"2019","journal-title":"Blood."},{"key":"B50","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1128\/MCB.14.3.1929","article-title":"Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency.","volume":"14","author":"Zhang","year":"1994","journal-title":"Mol Cell Biol."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000530","article-title":"Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex.","volume":"5","author":"Sato","year":"2009","journal-title":"PLoS Pathog."},{"key":"B52","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.4049\/jimmunol.163.11.6261","article-title":"Inactivation of NF-\u03baB by EBV BZLF-1-encoded ZEBRA protein in human T cells.","volume":"163","author":"Dreyfus","year":"1999","journal-title":"J Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1128\/mcb.14.3.1939","article-title":"The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B.","volume":"14","author":"Gutsch","year":"1994","journal-title":"Mol Cell Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2005-07-2730","article-title":"NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo.","volume":"107","author":"Keller","year":"2006","journal-title":"Blood."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/349612a0","article-title":"Activation of Epstein\u2013Barr virus latent genes protects human B cells from death by apoptosis.","volume":"349","author":"Gregory","year":"1991","journal-title":"Nature."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1038\/s41388-018-0147-x","article-title":"Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2.","volume":"37","author":"AlQarni","year":"2018","journal-title":"Oncogene."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02282-w","article-title":"PI3K\u03b4 activates E2F1 synthesis in response to mRNA translation stress.","volume":"8","author":"Gnanasundram","year":"2017","journal-title":"Nat Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.virol.2010.10.029","article-title":"Epstein-Barr virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin.","volume":"410","author":"Lu","year":"2011","journal-title":"Virology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.molcel.2005.02.029","article-title":"Structure of the p53 binding domain of HAUSP\/USP7 bound to Epstein-Barr nuclear antigen 1: implications for EBV-mediated immortalization.","volume":"18","author":"Saridakis","year":"2005","journal-title":"Mol Cell."},{"key":"B60","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1128\/JVI.02318-15","article-title":"Identification of MEF2B, EBF1, and IL6R as direct gene targets of Epstein-Barr virus (EBV) nuclear antigen 1 critical for EBV-infected B-lymphocyte survival.","volume":"90","author":"Tempera","year":"2015","journal-title":"J Virol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1099\/vir.0.83296-0","article-title":"Epstein\u2013Barr virus nuclear antigen-1 renders lymphocytes responsive to IL-2 but not IL-15 for survival.","volume":"89","author":"Tsimbouri","year":"2008","journal-title":"J Gen Virol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41388-019-1003-3","article-title":"The Epstein\u2013Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization.","volume":"39","author":"Wang","year":"2020","journal-title":"Oncogene."},{"key":"B63","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1128\/jvi.78.8.4108-4119.2004","article-title":"Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells.","volume":"78","author":"Cahir-McFarland","year":"2004","journal-title":"J Virol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.1725","article-title":"Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin\u2019s lymphoma cells through a mechanism involving Akt kinase and mTOR.","volume":"205","author":"Dutton","year":"2005","journal-title":"J Pathol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"16085","DOI":"10.1074\/jbc.274.23.16085","article-title":"Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates Interleukin-6 and Interleukin-8 production.","volume":"274","author":"Eliopoulos","year":"1999","journal-title":"J Biol Chem."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/sj.onc.1201694","article-title":"Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1).","volume":"16","author":"Eliopoulos","year":"1998","journal-title":"Oncogene."},{"key":"B67","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.1128\/jvi.00537-07","article-title":"Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras\/PI3-K\/Akt pathway.","volume":"81","author":"Fukuda","year":"2007","journal-title":"J Virol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1182\/blood-2004-07-2752","article-title":"EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX.","volume":"105","author":"Grimm","year":"2005","journal-title":"Blood."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/emboj\/17.6.1700","article-title":"Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.","volume":"17","author":"Kilger","year":"1998","journal-title":"EMBO J."},{"key":"B70","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.chom.2017.04.005","article-title":"CRISPR\/Cas9 screens reveal Epstein-Barr virus-transformed B cell host dependency factors.","volume":"21","author":"Ma","year":"2017","journal-title":"Cell Host Microbe."},{"key":"B71","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1128\/jvi.79.9.5499-5506.2005","article-title":"Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A.","volume":"79","author":"Moody","year":"2005","journal-title":"J Virol."},{"key":"B72","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1128\/JVI.71.9.6611-6618.1997","article-title":"Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation.","volume":"71","author":"Harada","year":"1997","journal-title":"J Virol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1073\/pnas.1019599108","article-title":"Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression.","volume":"108","author":"Maruo","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B74","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1073\/pnas.97.1.430","article-title":"Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter.","volume":"97","author":"Wang","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"B75","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.it.2014.01.003","article-title":"Cellular immune controls over Epstein\u2013Barr virus infection: new lessons from the clinic and the laboratory.","volume":"35","author":"Rickinson","year":"2014","journal-title":"Trends Immunol."},{"key":"B76","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-3-319-22834-1_11","article-title":"T-cell responses to EBV.","author":"Hislop","year":"2015","journal-title":"Epstein Barr Virus Volume 2: One Herpes Virus: Many Diseases."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005799","article-title":"Compartmentalization of total and virus-specific tissue-resident memory CD8+ T cells in human lymphoid organs.","volume":"12","author":"Woon","year":"2016","journal-title":"PLoS Pathog."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1084\/jem.187.9.1395","article-title":"Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo.","volume":"187","author":"Callan","year":"1998","journal-title":"J Exp Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.4049\/jimmunol.167.8.4450","article-title":"Differential evolution and stability of epitope-specific CD8+ T cell responses in EBV infection.","volume":"167","author":"Catalina","year":"2001","journal-title":"J Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jis646","article-title":"Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students.","volume":"207","author":"Balfour","year":"2013","journal-title":"J Infect Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1084\/jem.20112401","article-title":"Primary Epstein-Barr virus infection does not erode preexisting CD8+ T cell memory in humans.","volume":"209","author":"Odumade","year":"2012","journal-title":"J Exp Med."},{"key":"B82","first-page":"6219","article-title":"Epstein-Barr Virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin\u2019s disease patients: implications for a T-cell-based therapy.","volume":"61","author":"Chapman","year":"2001","journal-title":"Cancer Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.exger.2007.01.005","article-title":"Chronic herpesvirus reactivation occurs in aging.","volume":"42","author":"Stowe","year":"2007","journal-title":"Exp Gerontol."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007110","article-title":"Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection.","volume":"14","author":"Forrest","year":"2018","journal-title":"PLoS Pathog."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/eji.200940000","article-title":"Human peripheral blood and bone marrow Epstein\u2013Barr virus-specific T-cell repertoire in latent infection reveals distinct memory T-cell subsets.","volume":"40","author":"Guerreiro","year":"2010","journal-title":"Eur J Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4049\/jimmunol.1100590","article-title":"Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.","volume":"187","author":"Long","year":"2011","journal-title":"J Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jcyt.2018.08.001","article-title":"Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.","volume":"21","author":"Kalra","year":"2018","journal-title":"Cytotherapy."},{"key":"B88","doi-asserted-by":"publisher","first-page":"8649","DOI":"10.1128\/jvi.75.18.8649-8659.2001","article-title":"Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.","volume":"75","author":"Leen","year":"2001","journal-title":"J Virol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.20051287","article-title":"Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.","volume":"203","author":"Adhikary","year":"2006","journal-title":"J Exp Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.1128\/JVI.79.8.4896-4907.2005","article-title":"CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.","volume":"79","author":"Long","year":"2005","journal-title":"J Virol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1172\/JCI10209","article-title":"EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function.","volume":"107","author":"Bickham","year":"2001","journal-title":"J Clin Invest."},{"key":"B92","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1006\/viro.2001.1020","article-title":"Preferential utilization of the perforin\/granzyme pathway for lysis of Epstein\u2013Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells.","volume":"287","author":"Khanolkar","year":"2001","journal-title":"Virology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1182\/blood.V99.9.3302","article-title":"Cytokine production and cytolytic mechanism of CD4+cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus\u2013specific T-cell cultures.","volume":"99","author":"Sun","year":"2002","journal-title":"Blood."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.4049\/jimmunol.180.3.1643","article-title":"EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines.","volume":"180","author":"Haigh","year":"2008","journal-title":"J Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1084\/jem.20160248","article-title":"Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing.","volume":"213","author":"Tagawa","year":"2016","journal-title":"J Exp Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"E6467","DOI":"10.1073\/pnas.1605884113","article-title":"Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.","volume":"113","author":"Albanese","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B97","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2141.2005.05452.x","article-title":"The immune response to primary EBV infection: a role for natural killer cells.","volume":"129","author":"Williams","year":"2005","journal-title":"Br J Haematol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jaci.2019.11.049","article-title":"Identification of the first cases of complete CD16A deficiency: association with persistent EBV infection.","volume":"145","author":"Portilla","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0040027","article-title":"Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-\u03b3.","volume":"4","author":"Strowig","year":"2008","journal-title":"PLoS Pathog."},{"key":"B100","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1172\/JCI12932","article-title":"GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder.","volume":"108","author":"Baiocchi","year":"2001","journal-title":"J Clin Invest."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.celrep.2013.11.041","article-title":"Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection.","volume":"5","author":"Chijioke","year":"2013","journal-title":"Cell Rep."},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00607","article-title":"NKG2A-expressing natural killer cells dominate the response to autologous lymphoblastoid cells infected with Epstein-Barr virus.","volume":"7","author":"Hatton","year":"2016","journal-title":"Front Immunol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1099\/jgv.0.000369","article-title":"Repression of CIITA by the Epstein-Barr virus transcription factor Zta is independent of its dimerization and DNA binding.","volume":"97","author":"Balan","year":"2016","journal-title":"J Gen Virol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.4049\/jimmunol.0802686","article-title":"Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1073\/pnas.0611128104","article-title":"Host shutoff during productive Epstein\u2013Barr virus infection is mediated by BGLF5 and may contribute to immune evasion.","volume":"104","author":"Rowe","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1084\/jem.20070256","article-title":"A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in old world primates.","volume":"204","author":"Hislop","year":"2007","journal-title":"J Exp Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.4049\/jimmunol.0803218","article-title":"Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.","volume":"182","author":"Horst","year":"2009","journal-title":"J Immunol."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000255","article-title":"The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.","volume":"5","author":"Zuo","year":"2009","journal-title":"PLoS Pathog."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1128\/JVI.01608-10","article-title":"The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways.","volume":"85","author":"Zuo","year":"2011","journal-title":"J Virol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1128\/jvi.02183-15","article-title":"The missing link in Epstein-Barr virus immune evasion: the BDLF3 gene induces ubiquitination and down-regulation of major histocompatibility complex class I (MHC-I) and MHC-II.","volume":"90","author":"Quinn","year":"2016","journal-title":"J Virol."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005550","article-title":"The Epstein-Barr virus glycoprotein gp150 forms an immune-evasive glycan shield at the surface of infected cells.","volume":"12","author":"Gram","year":"2016","journal-title":"PLoS Pathog."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002704","article-title":"The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.","volume":"8","author":"Jochum","year":"2012","journal-title":"PLoS Pathog."},{"key":"B113","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2353\/ajpath.2008.070845","article-title":"Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin\u2019s lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells.","volume":"173","author":"Baumforth","year":"2008","journal-title":"Am J Pathol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.12659\/MSM.896629","article-title":"Classical Hodgkin lymphoma with positive Epstein-Barr virus status is associated with more FOXP3 regulatory T cells.","volume":"22","author":"Pavlovic","year":"2016","journal-title":"Med Sci Monit."},{"key":"B115","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/jclinpath-2016-203803","article-title":"Epstein\u2013Barr virus and regulatory T cells in Egyptian paediatric patients with acute B lymphoblastic leukaemia.","volume":"70","author":"Ateyah","year":"2017","journal-title":"J Clin Pathol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00277-018-3467-6","article-title":"Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and up-regulation of CD4 + CD25 + T cell ratio in early stage NK\/T cell lymphoma patients may predict worse outcome.","volume":"97","author":"Li","year":"2018","journal-title":"Ann Hematol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1182\/blood-2006-04-016923","article-title":"Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART.","volume":"108","author":"Epple","year":"2006","journal-title":"Blood."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00734","article-title":"Regulatory T cells as potential targets for HIV cure research.","volume":"9","author":"Kleinman","year":"2018","journal-title":"Front Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41375-018-0178-x","article-title":"Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.","volume":"33","author":"Anastasiadou","year":"2019","journal-title":"Leukemia."},{"key":"B120","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.4161\/cc.9.14.12267","article-title":"Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.","volume":"9","author":"Merkel","year":"2010","journal-title":"Cell Cycle."},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-52","article-title":"Epigenetic inactivation of mir-34b\/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.","volume":"12","author":"Wang","year":"2014","journal-title":"J Transl Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","article-title":"Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.","volume":"27","author":"Wang","year":"2015","journal-title":"Cell Signal."},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005642","article-title":"PD-1\/CTLA-4 blockade inhibits Epstein-Barr virus-induced lymphoma growth in a cord blood humanized-mouse model.","volume":"12","author":"Ma","year":"2016","journal-title":"PLoS Pathog."},{"key":"B124","doi-asserted-by":"publisher","first-page":"611","DOI":"10.4143\/crt.2018.191","article-title":"Comparison of efficacy of pembrolizumab between Epstein-Barr virus\u2013positive and\u2013negative relapsed or refractory non-hodgkin lymphomas.","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res Treat."},{"key":"B125","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/nrmicro3132","article-title":"Past, present and future: 30 years of HIV research.","volume":"11","author":"Barr\u00e9-Sinoussi","year":"2013","journal-title":"Nat Rev Microbiol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1084\/jem.20040874","article-title":"CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.","volume":"200","author":"Brenchley","year":"2004","journal-title":"J Exp Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1056\/nejm199501263320401","article-title":"Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.","volume":"332","author":"Cao","year":"1995","journal-title":"N Engl J Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1182\/blood-2003-09-3333","article-title":"Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.","volume":"104","author":"Deeks","year":"2004","journal-title":"Blood."},{"key":"B129","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1084\/jem.20041196","article-title":"Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract.","volume":"200","author":"Mehandru","year":"2004","journal-title":"J Exp Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1086\/314660","article-title":"Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.","volume":"179","author":"Giorgi","year":"1999","journal-title":"J Infect Dis."},{"key":"B131","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1172\/JCI117892","article-title":"CD8 naive T cell counts decrease progressively in HIV-infected adults.","volume":"95","author":"Roederer","year":"1995","journal-title":"J Clin Invest."},{"key":"B132","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.1128\/JVI.73.8.6715-6720.1999","article-title":"Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.","volume":"73","author":"Kalams","year":"1999","journal-title":"J Virol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1126\/science.278.5342.1447","article-title":"Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.","volume":"278","author":"Rosenberg","year":"1997","journal-title":"Science."},{"key":"B134","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0167-5699(93)90208-3","article-title":"A TH1\u2013TH2 switch is a critical step in the etiology of HIV infection.","volume":"14","author":"Clerici","year":"1993","journal-title":"Immunol Today."},{"key":"B135","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/QAD.0b013e3283344895","article-title":"HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells.","volume":"24","author":"Prendergast","year":"2010","journal-title":"AIDS."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1172\/JCI114376","article-title":"Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.","volume":"84","author":"Clerici","year":"1989","journal-title":"J Clin Invest."},{"key":"B137","first-page":"904","article-title":"Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles center, multicenter AIDS Cohort study.","volume":"6","author":"Giorgi","year":"1993","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B138","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1097\/00002030-200309050-00006","article-title":"Persistent immune activation in HIV-1 infection is associated with progression to AIDS.","volume":"17","author":"Hazenberg","year":"2003","journal-title":"AIDS."},{"key":"B139","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00042560-199710010-00003","article-title":"Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.","volume":"16","author":"Liu","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/infdis\/jiw146","article-title":"T-cell activation independently associates with immune senescence in HIV-infected recipients of long-term antiretroviral treatment.","volume":"214","author":"Group","year":"2016","journal-title":"J Infect Dis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/ni1515","article-title":"Up-regulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Nat Immunol."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/916936","article-title":"Elevation of Tim-3 and PD-1 expression on T cells appears early in HIV infection, and differential Tim-3 and PD-1 expression patterns can be induced by common \u03b3 -chain cytokines.","volume":"2015","author":"Zhang","year":"2015","journal-title":"BioMed Res Int."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0458-6","article-title":"Reduction of inflammation and T cell activation after 6 months of cART initiation during acute, but not in early chronic HIV-1 infection.","volume":"15","author":"de Paula","year":"2018","journal-title":"Retrovirology."},{"key":"B144","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1086\/524143","article-title":"Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.","volume":"197","author":"Hunt","year":"2008","journal-title":"J Infect Dis."},{"key":"B145","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.clim.2006.04.570","article-title":"Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function.","volume":"120","author":"Fernandez","year":"2006","journal-title":"Clin Immunol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1046\/j.1365-2249.1999.00806.x","article-title":"Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection.","volume":"115","author":"Steiner","year":"1999","journal-title":"Clin Exp Immunol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1182\/blood-2004-01-0365","article-title":"Human immunodeficiency virus\u2013driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients.","volume":"104","author":"Weiss","year":"2004","journal-title":"Blood."},{"key":"B148","article-title":"Update on evaluation of immune recovery following autologous hematopoietic cell transplantation in HIV-related lymphoma: results of the BMT CTN 0803\/AMC 071 trial","author":"Shindiapina","year":"2019","journal-title":"Late Breaking Poster Cession, Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR Poster LBA28."},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129488","article-title":"Comparative analysis of immune reconstitution in HIV-positive recipients of allogeneic and autologous stem cell transplant on the BMT CTN 0903\/AMC-080 and BMT CTN 0803\/AMC-071 trials.","author":"Shindiapina","year":"2019","journal-title":"Blood."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1182\/blood-2015-08-664706","article-title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803\/AMC 071 trial.","volume":"128","author":"Alvarnas","year":"2016","journal-title":"Blood."},{"key":"B151","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1086\/314868","article-title":"Early and persistent human immunodeficiency virus type 1 (HIV-1)\u2014specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection.","volume":"180","author":"Musey","year":"1999","journal-title":"J Infect Dis."},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00644","article-title":"Dynamic perturbations of the T-cell receptor repertoire in chronic HIV infection and following antiretroviral therapy.","volume":"6","author":"Heather","year":"2016","journal-title":"Front Immunol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1086\/367674","article-title":"Combination antiretroviral therapy results in a rapid increase in T cell receptor variable region \u03b2 repertoire diversity within CD45RA CD8 T cells in human immunodeficiency virus\u2013infected children.","volume":"187","author":"Kou","year":"2003","journal-title":"J Infect Dis."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02291","article-title":"Loss of T-cell multifunctionality and TCR-V\u03b2 repertoire against Epstein-Barr virus is associated with worse prognosis and clinical parameters in HIV(+) patients.","volume":"9","author":"Hern\u00e1ndez","year":"2018","journal-title":"Front Immunol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ajh.24370","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.","volume":"91","author":"Castillo","year":"2016","journal-title":"Am J Hematol."},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2009.032","article-title":"EBV and HIV-related lymphoma.","volume":"1","author":"Bibas","year":"2009","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"B157","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/QAD.0000000000000071","article-title":"Malignancies in HIV\/AIDS: from epidemiology to therapeutic challenges.","volume":"28","author":"Rubinstein","year":"2014","journal-title":"AIDS."},{"key":"B158","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/ajcp\/110.5.607","article-title":"Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations.","volume":"110","author":"Camilleri-Bro\u00ebt","year":"1998","journal-title":"Am J Clin Pathol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/0140-6736(91)91837-K","article-title":"Epstein-Barr virus in AIDS-related primary central nervous system lymphoma.","volume":"338","author":"MacMahon","year":"1991","journal-title":"Lancet."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1200\/jco.1993.11.9.1674","article-title":"Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression.","volume":"11","author":"Carbone","year":"1993","journal-title":"J Clin Oncol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.humpath.2009.07.024","article-title":"Epstein-Barr virus\u2013positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations.","volume":"41","author":"Hoeller","year":"2010","journal-title":"Hum Pathol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/j.1349-7006.2008.00813.x","article-title":"Age-related Epstein\u2013Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease.","volume":"99","author":"Shimoyama","year":"2008","journal-title":"Cancer Sci."},{"key":"B163","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/(sici)1097-0215(19970207)70:43.0.Co;2-t","article-title":"Epstein-Barr virus-associated Hodgkin\u2019s disease: epidemiologic characteristics in international data.","volume":"70","author":"Glaser","year":"1997","journal-title":"Int J Cancer."},{"key":"B164","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood.V88.2.645.bloodjournal882645","article-title":"Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi\u2019s sarcoma-associated herpes virus.","volume":"88","author":"Nador","year":"1996","journal-title":"Blood."},{"key":"B165","doi-asserted-by":"publisher","first-page":"941","DOI":"10.4065\/77.9.941","article-title":"Virology, pathogenetic mechanisms, and associated diseases of Kaposi Sarcoma-associated Herpesvirus (Human Herpesvirus 8).","volume":"77","author":"Sarid","year":"2002","journal-title":"Mayo Clin Proc."},{"key":"B166","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/apm.12078","article-title":"Epstein-Barr virus patterns in US Burkitt lymphoma tumors from the SEER residual tissue repository during 1979-2009.","volume":"122","author":"Mbulaiteye","year":"2014","journal-title":"APMIS."},{"key":"B167","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/23744235.2018.1508884","article-title":"A longitudinal and cross-sectional study ofEpstein-Barr virus DNA load: a possible predictor of AIDS-related lymphoma in HIV-infected patients.","volume":"50","author":"Hijlkema","year":"2018","journal-title":"Infect Dis."},{"key":"B168","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V82.2.619.619","article-title":"In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site.","volume":"82","author":"Hamilton-Dutoit","year":"1993","journal-title":"Blood."},{"key":"B169","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1468-1293.2012.00998.x","article-title":"Blood Epstein\u2013Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma.","volume":"13","author":"Leruez-Ville","year":"2012","journal-title":"HIV Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/qad.0000000000002129","article-title":"Epstein\u2013Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era.","volume":"33","author":"Lupo","year":"2019","journal-title":"AIDS."},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1099-2","article-title":"Blood Epstein\u2013Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma.","volume":"35","author":"Ul-Haq","year":"2018","journal-title":"Med Oncol."},{"key":"B172","first-page":"1073","article-title":"High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin\u2019s disease.","volume":"142","author":"Herndier","year":"1993","journal-title":"Am J Pathol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/0046-8177(95)90192-2","article-title":"Human immunodeficiency virus-associated Hodgkin\u2019s disease contains latent, not replicative, Epstein-Barr virus.","volume":"26","author":"Siebert","year":"1995","journal-title":"Hum Pathol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/QAD.0b013e328010ac5b","article-title":"Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein\u2013Barr virus status.","volume":"20","author":"Vaghefi","year":"2006","journal-title":"AIDS."},{"key":"B175","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07943.x","article-title":"Genome wide DNA-profiling of HIV-related B-cell lymphomas.","volume":"148","author":"Capello","year":"2010","journal-title":"Br J Haematol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/1535370214565992","article-title":"WWOX, large common fragile site genes, and cancer.","volume":"240","author":"Gao","year":"2015","journal-title":"Exp Biol Med."},{"key":"B177","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12026-010-8168-8","article-title":"HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.","volume":"48","author":"Epeldegui","year":"2010","journal-title":"Immunol Res."},{"key":"B178","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","article-title":"The tumor virus landscape of AIDS-related lymphomas.","volume":"125","author":"Arvey","year":"2015","journal-title":"Blood."},{"key":"B179","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3109\/10428199809057564","article-title":"Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS-related non-Hodgkin\u2019s lymphomas: correlation with histology and CD4-cell number.","volume":"30","author":"Kersten","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"B180","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imr.12502","article-title":"B-cell responses to HIV infection.","volume":"275","author":"Moir","year":"2017","journal-title":"Immunol Rev."},{"key":"B181","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ccr.2010.11.024","article-title":"Constitutive canonical NF-\u03baB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma.","volume":"18","author":"Calado","year":"2010","journal-title":"Cancer Cell."},{"key":"B182","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ccr.2010.10.030","article-title":"BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.","volume":"18","author":"Mandelbaum","year":"2010","journal-title":"Cancer Cell."},{"key":"B183","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.1182\/blood-2010-09-307710","article-title":"Down-regulation of BLIMP1\u03b1 by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas.","volume":"117","author":"Vrzalikova","year":"2011","journal-title":"Blood."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1128\/jvi.02781-14","article-title":"Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.","volume":"89","author":"Reusch","year":"2015","journal-title":"J Virol."},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.75","article-title":"Hypermethylation of the tumor suppressor gene PRDM1\/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma.","volume":"4","author":"Zhang","year":"2014","journal-title":"Blood Cancer J."},{"key":"B186","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-11-3169","article-title":"Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma.","volume":"18","author":"Chao","year":"2012","journal-title":"Clin Cancer Res."},{"key":"B187","year":"2019","journal-title":"Gap Report."},{"key":"B188","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/cam4.2710","article-title":"High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi.","volume":"9","author":"Montgomery","year":"2020","journal-title":"Cancer Med."},{"key":"B189","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.canep.2018.01.008","article-title":"First data from a population based cancer registry in Ethiopia.","volume":"53","author":"Timotewos","year":"2018","journal-title":"Cancer Epidemiol."},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-017-2841-0","article-title":"Cytokines associated with Burkitt\u2019s lymphoma in western Kenya.","volume":"10","author":"Ndede","year":"2017","journal-title":"BMC Res Notes."},{"key":"B191","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/infdis\/jiv525","article-title":"Impact of Plasmodium falciparum coinfection on longitudinal Epstein-Barr virus kinetics in Kenyan children.","volume":"213","author":"Reynaldi","year":"2016","journal-title":"J Infect Dis."},{"key":"B192","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1097\/00002030-200012220-00015","article-title":"Non-Hodgkin lymphoma in Uganda: a case\u2013control study.","volume":"14","author":"Parkin","year":"2000","journal-title":"AIDS."},{"key":"B193","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/pbc.21769","article-title":"Clinical characteristics and outcome of children with Burkitt lymphoma in Uganda according to HIV infection.","volume":"52","author":"Orem","year":"2009","journal-title":"Pediatr Blood Cancer."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/ijc.31537","article-title":"A case-control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda.","volume":"143","author":"Mpunga","year":"2018","journal-title":"Int J Cancer."},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-018-0195-4","article-title":"Plasmablastic lymphoma in Malawi.","volume":"13","author":"Zuze","year":"2018","journal-title":"Infect Agents Cancer."},{"key":"B196","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/978-981-10-7230-7_22","article-title":"Vaccine development for Epstein-Barr virus.","volume":"1045","author":"Cohen","year":"2018","journal-title":"Adv Exp Med Biol."},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-specific T cells for the immunocompromised patient.","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front Immunol."},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.7_suppl.146","article-title":"Suppression of EBV-induced LCLs using CAR T cells redirected against HLA-DR.","author":"Han","year":"2017","journal-title":"J Clin Oncol."},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2019-2310","article-title":"Abstract 2310: functional demonstration of CD19 chimeric antigen receptor (CAR) engineered Epstein-Barr virus (EBV) specific T cells: an off-the-shelf, allogeneic CAR T-cell immunotherapy platform.","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"key":"B200","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1182\/bloodadvances.2018022095","article-title":"Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE\/R in relapsed\/refractory HIV-positive lymphomas.","volume":"2","author":"Reid","year":"2018","journal-title":"Blood Adv."},{"key":"B201","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1182\/blood-2002-01-0210","article-title":"Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration.","volume":"100","author":"Porcu","year":"2002","journal-title":"Blood."},{"key":"B202","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/2326-6066.CIR-14-0242","article-title":"The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development.","volume":"3","author":"Hartlage","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117837","article-title":"BZLF1-DEC205 fusion protein enhances EBV-protective immunity in a spontaneous model of EBV-driven lymphoproliferative disease.","author":"Ahmed","year":"2018","journal-title":"Blood."},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126787","article-title":"Safety and efficacy of brentuximab vedotin in combination with AVD in stage II-IV HIV-associated classical Hodgkin lymphoma: results of the phase 2 study, AMC 085.","author":"Rubinstein","year":"2019","journal-title":"Blood."},{"key":"B205","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma.","volume":"378","author":"Connors","year":"2017","journal-title":"N Engl J Med."},{"key":"B206","first-page":"171","article-title":"First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen.","volume":"84","author":"Gu","year":"1995","journal-title":"Dev Biol Stand."},{"key":"B207","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein\u2013Barr virus vaccine in healthy adults.","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine."},{"key":"B208","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A phase I trial of Epstein-Barr virus Gp350 vaccine for children with chronic kidney disease awaiting transplantation.","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation."},{"key":"B209","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1158\/1078-0432.Ccr-17-2685","article-title":"Complete and durable responses in primary central nervous system posttransplant lymphoproliferative disorder with zidovudine, ganciclovir, rituximab, and dexamethasone.","volume":"24","author":"Dugan","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B210","first-page":"965","article-title":"Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.","volume":"63","author":"Roychowdhury","year":"2003","journal-title":"Cancer Res."},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/509296","article-title":"Advances in virus-directed therapeutics against Epstein-Barr virus-associated malignancies.","volume":"2012","author":"Ghosh","year":"2012","journal-title":"Adv Virol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood."},{"key":"B213","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood."},{"key":"B214","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest."},{"key":"B215","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma.","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/blood-2009-03-213256","article-title":"Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.","volume":"114","author":"Hanley","year":"2009","journal-title":"Blood."},{"key":"B218","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood."},{"key":"B219","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1182\/blood.V86.9.3287.bloodjournal8693287","article-title":"Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.","volume":"86","author":"Bernstein","year":"1995","journal-title":"Blood"},{"key":"B220","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1172\/JCI2038","article-title":"Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.","volume":"101","author":"Khatri","year":"1998","journal-title":"J Clin Invest."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01723\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T15:16:42Z","timestamp":1696778202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01723\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":220,"alternative-id":["10.3389\/fonc.2020.01723"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01723","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"article-number":"1723"}}